A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors
This study is testing a new medication called BL-M07D1 to see if it is safe and effective for treating various advanced solid tumors that have a specific protein called HER2. Researchers want to find the right dose and see how well it helps patients when other treatments might not have worked.
You may be able to join if you are 18 or older, have an advanced cancer with HER2 expression, have a life expectancy of at least 3 months, and agree to follow the study rules. However, you cannot join if you have had recent cancer treatments, major surgery, or certain serious heart conditions.
Participants will receive the study medication, BL-M07D1, while doctors carefully monitor your health and safety. You will have regular check-ins and tests to see how your body and your cancer respond to the treatment.
The study is currently recruiting participants at medical centers in Birmingham, Alabama, and Duarte and Los Angeles, California. More locations may become available over time.
- 1Testing a new medicine called BL-M07D1 for advanced cancers with HER2.
- 2Open to adults 18 and older who meet specific health and treatment history criteria.
- 3Currently recruiting patients at select locations in Alabama and California.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.